Bevacizumab (Avastin) continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Although better than the alternatives tested, still not good enough and shows the huge need for more research. They didn't include the Novocure NovoTTF-100A which is the only other approved treatment for recurrent GBMs and they did not include any of the exciting clinical trials.
Posted on: 10/10/2012
Br J Cancer. 2012 Oct 4. doi: 10.1038/bjc.2012.415. [Epub ahead of print]
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Reardon DA, Herndon JE 2nd, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ.
1] Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA  Department of Pediatrics, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA.
Background:Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries.Methods:We analysed outcome among all patients (n=99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome.Results:The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n=55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n=44; P=0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio=0.64; P=0.04).Conclusion:The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial.British Journal of Cancer advance online publication, 4 October 2012; doi:10.1038/bjc.2012.415www.bjcancer.com.
PMID: 23037712 [PubMed - as supplied by publisher]
Click HERE to return to brain tumor news headlines